AADI | tickerfilter.com

Fundamental analysis

31%

Profitability 0%

Dept financing 31%

Liquidity 75%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

-25.48%

3 Months

-18.91%

6 Months

2.66%

1 Year

-5.85%

2 Year

-76.97%

Key data

Stock price

$1.93

P/E Ratio

0.00

DAY RANGE

$1.86 - $2.09

EPS

-$2.28

52 WEEK RANGE

$1.21 - $3.81

52 WEEK CHANGE

-$11.06

MARKET CAP

50.707 M

YIELD

N/A

SHARES OUTSTANDING

24.615 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

-0.23

PUBLIC FLOAT

AVERAGE 10 VOLUME

$358,161

AVERAGE 30 VOLUME

$191,454

Company detail

CEO: Neil P. Desai
Region: US
Website: aadibio.com
Employees: 40
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin.

AADI - Aadi Bioscience, Inc.